Premium
Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia
Author(s) -
Xiao Yongtao,
Liu Runping,
Li Xiaojiaoyang,
Gurley Emily C.,
Hylemon Phillip B.,
Lu Ying,
Zhou Huiping,
Cai Wei
Publication year - 2019
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.30698
Subject(s) - biliary atresia , cholangiocyte , cholestasis , liver injury , medicine , fibrosis , cancer research , liver disease , biology , endocrinology , pathology , liver transplantation , transplantation
Biliary atresia (BA) is a neonatal liver disease featuring cholestasis and severe liver fibrosis (LF). Despite advances in the development of surgical treatment, lacking an early diagnostic marker and intervention of LF invariably leads to death from end‐stage liver disease in the early years of life. We previously reported that knockout of sphingosine 1‐phosphate receptor 2 (S1PR2) protected mice from bile duct ligation (BDL)‐induced cholangiocyte proliferation and LF. Our recent studies further showed that both hepatic and serum exosomal long noncoding RNA H19 (lncRNAH19) levels are correlated with cholestatic injury in multidrug resistance 2 knockout ( Mdr2 –/– ) mice. However, the role of lncRNAH19 in BA progression remains unclear. Here, we show that both hepatic and serum exosomal H19 levels are positively correlated with severity of fibrotic liver injuries in BA patients. H19 deficiency protects mice from BDL‐induced cholangiocyte proliferation and LF by inhibiting bile‐acid–induced expression and activation of S1PR2 and sphingosine kinase 2 (SphK2). Furthermore, H19 acts as a molecular sponge for members of the microRNA let‐7 family, which results in up‐regulation of high‐mobility group AT‐hook 2 (HMGA2), a known target of let‐7 and enhancement of biliary proliferation. Conclusion : These results indicate that H19 plays a critical role in cholangiocyte proliferation and cholestatic liver injury in BA by regulating the S1PR2/SphK2 and let‐7/HMGA2 axis. Serum exosomal H19 may represent a noninvasive diagnostic biomarker and potential therapeutic target for BA.